AVITA Medical, Inc. — fact timeline

Kathy McGee departed as Chief Operating Officer at AVITA Medical, Inc..

“Michael Holder, the Company’s Chief Financial Officer, and Kathy McGee, the Company’s Chief Operating Officer, are leaving the organization.”

Michael Holder changed role as Chief Financial Officer at AVITA Medical, Inc..

“Mr. Holder’s responsibilities as the Company’s principal financial officer and principal accounting officer will transition to Mr. Sean Ekins, as Interim Chief Financial Officer, effective immediately.”

AVITA Medical, Inc. shareholders approved Advisory Vote to Approve Compensation of Named Executive Officers at the 2022-12-12 meeting.

“Shareholders voted in favor of the non-binding advisory vote to approve the compensation of the Company’s named executive officers, by a vote of (i) 7,832,181 in favor, (ii) 2,381,954 against, and (iii) 770,852 abstaining.”

AVITA Medical, Inc. shareholders approved Issuance of Securities to Mr. James Corbett at the 2022-12-12 meeting.

“Shareholders approved the grant of options to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$1,000,000 (at the time of the grant) to Mr. James Corbett on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11, by a vote of (i) 8,476,617 in favor, (ii) 1,869,887 against, and (iii) 638,483 abstaining.”

AVITA Medical, Inc. shareholders approved Issuance of Securities to Ms. Jan Stern Reed at the 2022-12-12 meeting.

“Shareholders approved the grant of restricted stock units to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$87,500 (at the time of the grant) and the grant of options to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$37,500 (at the time of the grant) to Ms. Jan Stern Reed on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11, by a vote of (i) 7,657,643 in favor, (ii) 2,674,563 against, and (iii) 652,781 abstaining.”

AVITA Medical, Inc. shareholders approved Issuance of Securities to Mr. Jeremy Curnock Cook at the 2022-12-12 meeting.

“Shareholders approved the grant of restricted stock units to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$87,500 (at the time of the grant) and the grant of options to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$37,500 (at the time of the grant) to Mr. Jeremy Curnock Cook on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11, by a vote of (i) 7,612,792 in favor, (ii) 2,745,543 against, and (iii) 626,652 abstaining.”

AVITA Medical, Inc. shareholders approved Issuance of Securities to Professor Suzanne Crowe at the 2022-12-12 meeting.

“Shareholders approved the grant of restricted stock units to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$87,500 (at the time of the grant) and the grant of options to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$37,500 (at the time of the grant) to Professor Suzanne Crowe on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11, by a vote of (i) 7,656,800 in favor, (ii) 2,666,551 against, and (iii) 661,636 abstaining.”

AVITA Medical, Inc. shareholders approved Issuance of Securities to Mr. Louis Panaccio at the 2022-12-12 meeting.

“Shareholders approved the grant of restricted stock units to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$87,500 (at the time of the grant) and the grant of options to acquire shares of common stock of the Company (which may be represented by CDIs) equal in value to US$37,500 (at the time of the grant) to Mr. Louis Panaccio on the terms and conditions set out in this Proxy Statement, pursuant to and for the purposes of ASX Listing Rule 10.11, by a vote of (i) 7,637,405 in favor, (ii) 2,735,159 against, and (iii) 612,423 abstaining.”

AVITA Medical, Inc. shareholders rejected Amendments to the Company's Amended and Restated Bylaws to reduce the quorum requirement for stockholder meetings at the 2022-12-12 meeting.

“Shareholders did not approve amendments to the Company’s Certificate of Incorporation and Amended and Restated Bylaws to reduce the quorum requirement for stockholder meetings, on the terms and conditions set out in the Proxy Statement, by a vote of (i) 9,587,285 in favor, (ii) 956,344 against, and (iii) 441,358 abstaining.”

AVITA Medical, Inc. shareholders approved Appointment of Independent Auditors at the 2022-12-12 meeting.

“The appointment of Grant Thornton LLP as the Company’s independent public accountants for the fiscal year ending December 31, 2022, was ratified by a vote of (i) 12,430,789 in favor, (ii) 224,743 against, and (iii) 258,367 abstaining.”

AVITA Medical, Inc. shareholders approved Election of Directors at the 2022-12-12 meeting.

“All five directors named in the Company’s Proxy Statement for the Annual Meeting (“Proxy Statement”) were elected to serve on the Company’s Board of Directors with the following vote: Name Votes For Votes Withheld Non-Votes Louis Panaccio ( Chair ) 9,299,761 1,685,226 1,928,912 James Corbett ( Executive Director and CEO ) 10,360,740 624,247 1,928,912 Jeremy Curnock Cook ( Director ) 9,803,894 1,181,093 1,928,912 Professor Suzanne Crowe ( Director ) 9,216,541 1,768,446 1,928,912 Jan Stern Reed ( Director ) 9,926,444 1,058,543 1,928,912”

AVITA Medical, Inc. reported full year 2022 results: revenue $33.0-34.0 million. Guidance raised.

“full year 2022 commercial revenue (excluding BARDA revenues) is expected to be $33.0-34.0 million, an increase from our prior guidance of $30 million”

AVITA Medical, Inc. reported third quarter ended September 30, 2022 results: revenue $9.0 million, net income $5.6 million, EPS $0.22 per share.

“Reported commercial revenue, which excludes BARDA revenue, of $9.0 million, a 30% increase compared to $6.9 million in the corresponding period in the prior year”

James Corbett was appointed as President and CEO at AVITA Medical, Inc..

“Effective September 28, 2022, the Board of Directors of the Company appointed James Corbett as the Company’s President and CEO.”

Michael Perry was terminated as President and CEO at AVITA Medical, Inc..

“Effective September 28, 2022, the Board of Directors of Avita Medical, Inc. (the “Company”) terminated the employment of Dr. Michael Perry, the Company’s President and CEO.”

Louis Drapeau departed as Non-Executive Director at AVITA Medical, Inc..

“On April 19, 2022, Non-Executive Director Louis Drapeau notified the Chair of the Board of Directors of AVITA Medical, Inc. (the “Company”) that due to changed personal circumstances, Mr. Drapeau is resigning from the Board of Directors.”